By Michele Maatouk
Date: Tuesday 31 Mar 2026
(Sharecast News) - Shares in Apellis Pharmaceuticals rocketed on Tuesday after it agreed to be bought by Biogen in a $5.6bn deal.
| Currency | US Dollars |
| Share Price | $ 227.53 |
| Change Today | $ 2.17 |
| % Change | 0.96 % |
| 52 Week High | $229.19 |
| 52 Week Low | $135.67 |
| Volume | 1,494,257 |
| Shares Issued | 146.80m |
| Market Cap | $33,401m |
| RiskGrade | 259 |
| Strong Buy | 10 |
| Buy | 9 |
| Neutral | 13 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 33 |

| Time | Volume / Share Price |
| 15:59 | 100 @ $227.51 |
| 15:59 | 225 @ $227.52 |
| 15:59 | 170 @ $227.52 |
| 15:59 | 100 @ $227.45 |
| 15:59 | 100 @ $227.43 |
You are here: research